RayKnowChina Research Map
Shortlist

NanjingNanjing Medical University

Children's Hospital of Nanjing Medical University

南京市儿童医院

Listed for 16 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Children's Hospital of Nanjing Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatoblastoma肝母细胞瘤3 papers led
  2. Osteosarcoma骨肉瘤1 paper led
  3. Neuroblastoma神经母细胞瘤15 papers led1 open trial led
  4. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
  5. Haemophilia A血友病 A0 papers led
  6. Biliary atresia胆道闭锁9 papers led
  7. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  8. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  9. Fabry disease法布雷病0 papers led
  10. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  11. Behçet disease白塞病2 papers led
  12. Alport syndromeAlport 综合征0 papers led
  13. IgA nephropathyIgA 肾病1 paper led
  14. Gaucher disease戈谢病0 papers led
  15. Hirschsprung disease先天性巨结肠9 papers led
  16. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatoblastoma

肝母细胞瘤

Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

1 hospital in Nanjing for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

21 hospitals in Nanjing for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Circ-FOXM1 promotes the proliferation, migration and EMT process of osteosarcoma cells through FOXM1-mediated Wnt pathway activation.2022Journal of orthopaedic surgery and research
Chinese-language papers (not in the count)1
  1. [Panax notoginseng saponins inhibit proliferation, migration, invasion and promote apoptosis of U2OS osteosarcoma cells via blocking Notch1 pathway].2021Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 15 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 1.3%.

Papers led
15
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 3320232024: 5520242025: 222025

10 hospitals in Nanjing for neuroblastoma321 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06751134

    Age 1 year to 12 years (registered criteria)

    Led by Children's Hospital of Nanjing Medical UniversityNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine
Papers it led15
  1. Cellular morphometric biomarkers and large language model predict prognosis and treatment response in neuroblastoma patients: A retrospective and double-blind prospective single arm clinical study.2025European journal of cancer (Oxford, England : 1990)
  2. RAS gene polymorphisms confer the risk of neuroblastoma in Chinese children from Jiangsu province.2025Pediatric surgery international
  3. Clinical features and treatment options for pediatric adrenal incidentalomas: a retrospective single center study.2024BMC pediatrics
  4. HOTTIP rs1859168 C > A polymorphism reduces neuroblastoma susceptibility in Chinese children.2024European journal of pediatrics
  5. Combination of Losartan and Platinum Nanoparticles with Photothermal Therapy Induces Immunogenic Cell Death Effective Against Neuroblastoma.2024International journal of nanomedicine
  6. Cell communication pathway prognostic model identified detrimental neurodevelopmental pathways in neuroblastoma.2024Neoplasia (New York, N.Y.)
  7. E2F1 induced neuroblastoma cell migration and invasion via activation of CENPE/FOXM1 signaling pathway.2024The International journal of neuroscience
  8. GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway.2023Anti-cancer drugs
  9. Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts.2023Archives of toxicology
  10. Construction of a novel anoikis-related prognostic model and analysis of its correlation with infiltration of immune cells in neuroblastoma.2023Frontiers in immunology
  11. Lipid emulsion-induced hypertension post resection of pediatric neuroblastoma: a case report and literature review.2022BMC pediatrics
  12. Identification of hub genes and their correlation with infiltration of immune cells in MYCN positive neuroblastoma based on WGCNA and LASSO algorithm.2022Frontiers in immunology
  13. The long noncoding RNA LINC00200 promotes the malignant progression of MYCN-amplified neuroblastoma via binding to insulin like growth factor 2 mRNA binding protein 3 (IGF2BP3) to enhance the stability of Zic family member 2 (ZIC2) mRNA.2022Pathology, research and practice
  14. Verification of genetic differences and immune cell infiltration subtypes in the neuroblastoma tumour microenvironment during immunotherapy.2022World journal of surgical oncology
  15. The inhibition of GHR enhanced cytotoxic effects of etoposide on neuroblastoma.2021Cellular signalling
Earlier papers (2016–2020)3
  1. Comparison of Incidence and Outcomes of Neuroblastoma in Children, Adolescents, and Adults in the United States: A Surveillance, Epidemiology, and End Results (SEER) Program Population Study.2020Medical science monitor : international medical journal of experimental and clinical research
  2. Association of miR-146a, miR-149 and miR-196a2 polymorphisms with neuroblastoma risk in Eastern Chinese population: a three-center case-control study.2019Bioscience reports
  3. RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway.2019FEBS open bio
All its trials on ClinicalTrials.gov, any status2
  1. Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory NeuroblastomaRecruitingNCT06751134Lead sponsorPhase 1Start 2024-12
  2. Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in ChildrenStatus unknownNCT02919046Study siteN/AStart 2016-09

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Nanjing for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  4. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildren
Departments in papersMedical oncology
Papers it led1
  1. Identification of a novel MEF2C::SS18L1 fusion in childhood acute B-lymphoblastic leukemia.2024Journal of cancer research and clinical oncologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  2. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  3. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  4. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)RecruitingNCT05667506Study sitePhase 1/Phase 2Start 2023-02

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Nanjing for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 9 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 4.2%.

Papers led
9
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 552025

1 hospital in Nanjing for biliary atresia31 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDisease mechanismsKasai operationScreening & diagnosis
Departments in papersPediatricsRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led9
  1. EP300/YAP1-SERPINE1 Signaling Regulates Ductular Reaction and Liver Fibrosis in Biliary Atresia.2026Cellular and molecular gastroenterology and hepatologyFree full text
  2. PRAG1 promotes cholangiocyte epithelial-mesenchymal transition and liver fibrosis in biliary atresia.2025Biochimica et biophysica acta. Molecular basis of disease
  3. CTHRC1 serves as an indicator in biliary atresia for evaluating the stage of liver fibrosis and predicting prognosis.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  4. Correlation Analysis Between Preoperative Liver Ultrasound Elastography and Postoperative Jaundice Clearance After Kasai Surgery for Biliary Atresia.2025Journal of pediatric surgery
  5. Dysregulated Activation of Hippo-YAP1 Signaling Induces Oxidative Stress and Aberrant Development of Intrahepatic Biliary Cells in Biliary Atresia.2025Laboratory investigation; a journal of technical methods and pathology
  6. Development and validation of a nomogram for predicting the clearance of jaundice in children with biliary Atresia after Kasai portoenterostomy.2025Langenbeck's archives of surgeryRCTFree full text
  7. A convenient nomogram for predicting early death or liver transplantation after the Kasai procedure in patients with biliary atresia.2024Langenbeck's archives of surgery
  8. The difference of gut microbiome in different biliary diseases in infant before operation and the changes after operation.2022BMC pediatricsFree full text
  9. RRV-induced biliary atresia in neonatal mice involves CD8 + T lymphocyte killer cells and the Notch signaling pathway.2021Genes & genomics
All its trials on ClinicalTrials.gov, any status2
  1. Definition for Biliary Atresia Associated Cholangitis After SurgeryStatus unknownNCT05464303Lead sponsorStart 2022-07
  2. Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai ProcedureStatus unknownNCT05909033Lead (inferred)Start 2017-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanjing for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Nanjing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Clinical characteristics of 6 children with idiopathic interstitial pneumonia].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)1
  1. [Bronchitis obliterans associated with bronchiolitis obliterans with organizing pneumonia in a child and literature review].2016Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Nanjing for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)2
  1. [An ADTKD pedigree discovered from Fabry disease screening].2025Zhonghua nei ke za zhi
  2. [A case of adolescent Fabry disease with end-stage renal disease].2023Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467Study siteStart 2021-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanjing for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Chinese-language papers (not in the count)1
  1. [Analysis of clinical characteristics and genetic variants in two children with Limb-girdle muscular dystrophy autosomal recessive 9 FKRP-related].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

5 hospitals in Nanjing for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Nanjing for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)1
  1. [Advances in gene therapy for Alport syndrome].2024Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Nanjing for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. A rare case of late-onset immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome confused with IgA vasculitis nephropathy.2025Pediatric nephrology (Berlin, Germany)
All its trials on ClinicalTrials.gov, any status1
  1. RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune DiseasesNot yet recruitingNCT07674147Study siteEarly phase 1Start 2026-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Nanjing for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Chinese-language papers (not in the count)1
  1. [Clinical phenotype and genotype of Gaucher disease in 14 children].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 9 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 5.6%.

Papers led
9
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 1120242025: 442025

3 hospitals in Nanjing for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led9
  1. Features of defecation dysfunction among patients with Hirschsprung disease in early childhood.2025BMC gastroenterology
  2. Extracellular vesicle-mediated transfer of MIR22HG inhibits the colonization of enteric neural crest cells in the colon by decreasing MPP3 expression.2025Communications biology
  3. For short-segment Hirschsprung disease, daily trans-anal irrigation before pull-through surgery is necessary?2025Pediatric research
  4. Comparative efficacy of Soave versus Swenson procedures for Hirschsprung disease: a systematic review and meta-analysis.2025Pediatric surgery international
  5. Mechanism of Endogenous Peptide PDYBX1 and Precursor Protein YBX1 in Hirschsprung's Disease.2024Neuroscience bulletin
  6. Bowel function at preschool and early childhood age in children with long-segment Hirschsprung disease.2023European journal of pediatrics
  7. Multiple 'omics'-analysis reveals the role of prostaglandin E2 in Hirschsprung's disease.2021Free radical biology & medicine
  8. Peptide Derived from AHNAK Inhibits Cell Migration and Proliferation in Hirschsprung's Disease by Targeting the ERK1/2 Pathway.2021Journal of proteome research
  9. m6A demethylase ALKBH5 suppresses proliferation and migration of enteric neural crest cells by regulating TAGLN in Hirschsprung's disease.2021Life sciences
Earlier papers (2016–2020)23
  1. Application of enhanced recovery after surgery during the perioperative period in infants with Hirschsprung's disease - A multi-center randomized clinical trial.2020Clinical nutrition (Edinburgh, Scotland)RCT
  2. Molecular function predictions and diagnostic value analysis of plasma exosomal miRNAs in Hirschsprung's disease.2020Epigenomics
  3. Prospective study reveals a microbiome signature that predicts the occurrence of post-operative enterocolitis in Hirschsprung disease (HSCR) patients.2020Gut microbes
  4. Circular RNA CCDC66 targets DCX to regulate cell proliferation and migration by sponging miR-488-3p in Hirschsprung's disease.2019Journal of cellular physiology
  5. MPGES-1 derived PGE2 inhibits cell migration by regulating ARP2/3 in the pathogenesis of Hirschsprung disease.2019Journal of pediatric surgery
  6. Feasibility and efficacy of home rectal irrigation in neonates and early infancy with Hirschsprung disease.2019Pediatric surgery internationalRCT
  7. Down-regulation of circ-PRKCI inhibits cell migration and proliferation in Hirschsprung disease by suppressing the expression of miR-1324 target PLCB1.2018Cell cycle (Georgetown, Tex.)
  8. Long non-coding RNA LOC100507600 functions as a competitive endogenous RNA to regulate BMI1 expression by sponging miR128-1-3p in Hirschsprung's disease.2018Cell cycle (Georgetown, Tex.)
  9. Long non-coding RNA FAL1 functions as a ceRNA to antagonize the effect of miR-637 on the down-regulation of AKT1 in Hirschsprung's disease.2018Cell proliferation
  10. Identification of two novel PCDHA9 mutations associated with Hirschsprung's disease.2018Gene
  11. IGF2-derived miR-483-3p associated with Hirschsprung's disease by targeting FHL1.2018Journal of cellular and molecular medicine
  12. Lipopolysaccharide enhances ADAR2 which drives Hirschsprung's disease by impairing miR-142-3p biogenesis.2018Journal of cellular and molecular medicine
  13. Aberrant expression of LncRNA-MIR31HG regulates cell migration and proliferation by affecting miR-31 and miR-31* in Hirschsprung's disease.2018Journal of cellular biochemistry
  14. MicroRNA-939 inhibits cell proliferation via targeting LRSAM1 in Hirschsprung's disease.2017Aging
  15. LncRNA AFAP1-AS Functions as a Competing Endogenous RNA to Regulate RAP1B Expression by sponging miR-181a in the HSCR.2017International journal of medical sciences
  16. Single-stage transanal endorectal pull-through procedure for correction of Hirschsprung disease in neonates and nonneonates: A multicenter study.2017Journal of pediatric surgery
  17. Exome-Wide Association Study Identified New Risk Loci for Hirschsprung's Disease.2017Molecular neurobiology
  18. Circular RNA ZNF609 functions as a competitive endogenous RNA to regulate AKT3 expression by sponging miR-150-5p in Hirschsprung's disease.2017Oncotarget
  19. Role of MiR-215 in Hirschsprung's Disease Pathogenesis by Targeting SIGLEC-8.2016Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  20. Downregulated Expression of Long Non-Coding RNA LOC101926975 Impairs both Cell Proliferation and Cell Cycle and Its Clinical Implication in Hirschsprung Disease Patients.2016International journal of medical sciences
  21. Apoptotic neuron-secreted HN12 inhibits cell apoptosis in Hirschsprung's disease.2016International journal of nanomedicine
  22. Suppressive action of miRNAs to ARP2/3 complex reduces cell migration and proliferation via RAC isoforms in Hirschsprung disease.2016Journal of cellular and molecular medicine
  23. Microarray expression profiling of dysregulated long non-coding RNAs in Hirschsprung's disease reveals their potential role in molecular diagnosis.2016Neurogastroenterology and motility
All its trials on ClinicalTrials.gov, any status2
  1. Risk Factors for Bowel Dysfunction at Preschool and Early Childhood Age in Children With Hirschsprung DiseaseStatus unknownNCT05655845Lead (inferred)Start 2022-08
  2. The Long Term Outcomes After Pull-through of Long Segment Hirschsprung DiseaseStatus unknownNCT05461924Lead (inferred)Start 2022-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Nanjing for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Chinese-language papers (not in the count)1
  1. [Diagnosis and treatment of familial adenomatous polyposis in children].2023Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

南京市儿童医院

Children's Hospital of Nanjing Medical University

南京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Affiliated Children's Hospital of Nanjing Medical University; Nanjing Children's Hospital; Fourth Hospital of Nanjing; Jiangsu Second Red Cross Hospital; Second Affiliated Hospital of Nanjing Medical University; Second Clinical Hospital of Nanjing Medical University

Suggest a correctionDownload the data